About DEFLUX

DEFLUX was developed during the 1990s specifically with the goal of fulfilling the criteria of an ideal profile for an injectable material including:

• Biocompatibility allowing good tissue tolerance
• Durability
• Lack of migration from the injection site
• Ease of use
• High response rates

DEFLUX was approved for use and  CE marked in Europe in 1998 for the treatment of all grades of VUR. Approval from the US Food and Drug Administration (FDA) was gained for DEFLUX in 2001 for the treatment of childhood VUR grades II – IV.